Stock AnalizPhilip Morris International Inc. PM
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Philip Morris International Inc. (PM) is a healthcare company listed in the US with a market value of about $310.1B. In the twelve months to September 30, 2026 it had revenue of $43.1B and net income of $10.7B, a net margin of 24.8%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).
Key numbers: a P/E of 29.0, a price to free cash flow of 22.8, 5-year revenue growth of 7% a year, a 5-year average ROIC of 34%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.
Score: 1.6 / 5
Checks passed
- Profit margin improving
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.1B | $40.6B | $37.9B | $35.2B | $31.8B | $31.4B | $28.7B | $29.8B | $29.6B | $78.1B | $75.0B |
| Net income | $10.7B | $11.3B | $7.1B | $7.8B | $9.0B | $9.1B | $8.1B | $7.2B | $7.9B | $6.0B | $7.0B |
| Free cash flow | $13.6B | $10.7B | $10.8B | $7.9B | $9.7B | $11.2B | $9.2B | $9.2B | $8.0B | $7.4B | $6.9B |
| EPS (diluted) | $6.85 | $7.26 | $4.52 | $5.02 | $5.81 | $5.83 | $5.16 | $4.61 | $5.08 | $3.88 | $4.48 |
| Net margin | 24.8% | 27.9% | 18.6% | 22.2% | 28.5% | 29.0% | 28.1% | 24.1% | 26.7% | 7.7% | 9.3% |
| ROIC | — | 30.3% | 29.3% | 25.4% | 30.7% | 56.3% | 47.0% | 40.6% | 47.2% | 31.6% | 50.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $212.44, 7% above the current price; targets range from $175.00 to $240.00; the consensus rating is “Buy”; expected EPS is $8.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Philip Morris International’s P/E ratio?
About 29.0, based on the last twelve months of diluted earnings per share (forward P/E about 23.7).
Is Philip Morris International stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Philip Morris International pay a dividend?
Yes. The dividend yield is about 3.26%, and it has paid dividends for 10 years in our data.
Is Philip Morris International a good stock to buy?
We do not give buy or sell advice. Philip Morris International scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.